AbbVie’s 2025 revenue exceeds $60 billion, with a 14% increase in immunology revenue

K-LinePoet · 2026-03-05T02:02:18+00:00

AbbVie’s global revenue in 2025 reached $61.16 billion, an increase of 8.6% year-over-year, entering the $60 billion club. Revenue in the immunology field was $30.406 billion, up 14%, with Skyrizi and UpaTeni showing excellent performance, increasing by 49.9% and 39.1% respectively. These two drugs were also quickly approved in the Chinese market, expanding treatment options for patients.

K-LinePoet

2026-03-05 02:02:18

Abstract generation in progress

The Beijing News (Reporter Wang Kala) reports that global pharmaceutical companies have recently announced their full-year 2025 results. Amid increasing competition, the multinational pharmaceutical company AbbVie achieved an 8.6% year-over-year increase in global revenue, reaching $61.16 billion and officially entering the $600 billion global club. Both revenue and growth rate place AbbVie among the top three worldwide; net profit was 4.233 billion yuan, a slight decrease of 1.24% year-over-year.

In the field of immunology, AbbVie’s revenue in 2025 reached $30.406 billion, a 14% increase year-over-year. The “twin stars” in immunology, Skyrizi (risankizumab) and Upadacitinib, continue to attract industry attention due to their sustained high growth. Thanks to the accelerated expansion of indications worldwide, in 2025, Skyrizi’s global sales reached $17.562 billion, a 49.9% increase, with outstanding performance in inflammatory bowel disease (IBD). The new patient initiation rate for Crohn’s disease and ulcerative colitis reached 40%-50%, aligning with the global IBD market’s 15% annual growth rate; Upadacitinib’s global sales reached $8.304 billion, a 39.1% increase. Currently, Upadacitinib has been approved in Europe and the U.S. for adult giant cell arteritis.

In China, these two drugs are keeping pace with global developments and are accelerating to benefit more patients. In January this year, Skyrizi was approved in China for moderate to severe active ulcerative colitis in adults, further expanding treatment options for Chinese IBD patients, including those with Crohn’s disease. Meanwhile, the development of Upadacitinib for indications such as alopecia areata and vitiligo is also accelerating, with approvals expected by 2026.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.